Comment from Anthropic

Summary: Anthropic, an AI safety and research company, supports the FDA's pilot program but recommends a framework that distinguishes between the obligations of the AI tool sponsor and the developer of the underlying general-purpose model. They argue for architecture-neutral technology selection, structured provenance documentation for training data, and a managed lifecycle for model versioning rather than a general requirement to freeze model versions during a trial.